Anbio Biotechnology

21.65-1.69 (-7.24%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · NNNN · USD

Upcoming Earnings

Report date
-

Key Stats

Market Cap
950.24M
P/E (TTM)
433.00
Basic EPS (TTM)
0.05
Dividend Yield
0%

About

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

CEO
Mr. Michael Lau M.B.A., Ph.D.
IPO
2/19/2025
Employees
27
Sector
Healthcare
Industry
Medical Instruments & Supplies